Tag: PFA
Abbott, Medtronic announce positive data on respective PFA systems at HRS...
Among a great number of presentations relating to pulsed field ablation (PFA) treatments for atrial fibrillation (AF) at this year’s Heart Rhythm Society (HRS)...
Kardium announces “impressive” one-year PULSAR IDE study results with Globe PF system
Kardium has announced late-breaking, one-year clinical trial results with its innovative pulsed field ablation (PFA) device—the Globe PF system.
Pivotal findings from the PULSAR...
Field Medical announces promising first-in-human data on treating scar-related VT using...
Field Medical has announced that its FieldForce ablation system was recently featured in a scientific presentation at the 2025 Heart Rhythm Society (HRS) annual...
Second phase of Boston’s ADVANTAGE AF study meets primary safety and...
Boston Scientific has announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the...
J&J MedTech presents new Omny-IRE and VARIPURE study data at HRS...
Johnson & Johnson (J&J) MedTech has announced positive initial three-month results from the Omny-IRE study evaluating the investigational Omnypulse platform in patients with paroxysmal...
Field Medical closes US$40 million Series A financing to advance PFA...
Field Medical has announced the successful closing of US$40 million in Series A financing. The round includes US$20 million in new capital and the conversion of US$20 million in seed-round...
SINGLE SHOT CHAMPION data leave “no doubt” that PFA is non-inferior...
At this year’s European Heart Rhythm Association (EHRA) congress (30 March–1 April 2025, Vienna, Austria), a late-breaking presentation of data from the SINGLE SHOT...
Medtronic announces first patient enrolment in trial assessing VT treatment with...
Medtronic recently announced that the first patient has been enrolled in a US Food and Drug Administration (FDA) early feasibility study evaluating the Affera...
J&J’s dual-energy ablation catheter deemed safe and effective in first-in-human SmartfIRE...
Johnson & Johnson (J&J) MedTech has today announced 12-month results from the SmartfIRE study, delivered as a late-breaking presentation at the ongoing European Heart...
Farapulse PFA system demonstrates superior efficacy to cryoablation catheter in paroxysmal...
New findings from the SINGLE SHOT CHAMPION trial, presented at the ongoing European Heart Rhythm Association (EHRA) congress (30 March–1 April 2025, Vienna, Austria)...
MedLumics announces publication of first-in-human results with AblaView PFA system
MedLumics has announced the publication of first-in-human results for the AblaView pulsed field ablation (PFA) system in atrial fibrillation (AF) patients, including clinical safety...
Medtech insight: Pulsed field ablation is a “once-in-a-career opportunity”
Boston Scientific’s vice president (VP) of rhythm management, Caroline Bravo, speaks to Cardiac Rhythm News about the arrival of pulsed field ablation (PFA) for...
Boston Scientific obtains CE mark for next generation of cardiac mapping...
Boston Scientific Corporation has announced it has received CE-mark approval for its navigation-enabled Farawave Nav ablation catheter in the treatment of paroxysmal atrial fibrillation...
Cardiac Rhythm News’ top stories of 2024
From first-time clinical data to major industry debuts, here are Cardiac Rhythm News’ 10 most popular stories of 2024.
1. Abbott joins the pulsed field...
BTL Medical announces successful first-in-human treatments with novel PFA catheter
BTL Medical has announced the successful treatment of the first six patients in a first-in-human feasibility study using its next-generation catheter system designed to...
Pulse appoints David Kenigsberg as Electrophysiology CMO and adds Andrea Natale...
Pulse Biosciences has announced the appointment of David Kenigsberg (Florida Heart Rhythm Specialists, Fort Lauderdale, USA) as chief medical officer (CMO) of Electrophysiology. In...
J&J MedTech receives US FDA approval for Varipulse PFA platform in...
Johnson & Johnson (J&J) MedTech has announced the US Food and Drug Administration (FDA) approval of the Varipulse pulsed field ablation (PFA) platform for...
MedLumics treats first 10 patients in AblaView clinical study and announces...
MedLumics recently announced that 10 patients have been treated in the company’s first-in-man clinical trial, which is ongoing and currently under protocol-dictated follow-up. The...
Boston Scientific launches next generation of cardiac mapping for Farapulse PFA...
Boston Scientific Corporation has announced that it has received US Food and Drug Administration (FDA) approval of the navigation-enabled Farawave Nav ablation catheter for...
Abbott progresses PFA clinical studies, launches new advanced cardiac mapping technology
Abbott announced today that it has achieved new, major milestones to support the company's growing suite of pulsed field ablation (PFA) solutions in electrophysiology.
These...
Boston Scientific receives Japanese regulatory approval for Farapulse PFA system
Boston Scientific has announced receipt of Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for the Farapulse pulsed field ablation (PFA) system. The...
New clinical data show “excellent lesion durability” with Medtronic’s PulseSelect PFA...
Medtronic has announced the presentation of clinical study results demonstrating a high rate of durable lesion formation with the PulseSelect pulsed field ablation (PFA)...
PULSE-EU: single-shot spherical array PFA catheter achieves good clinical efficacy at...
The treatment of atrial fibrillation (AF) via a novel, ‘single-shot’ spherical array approach to pulsed field ablation (PFA) has been found to achieve durable...
Advertorial: PFA is now “beyond the phase of excitement”
This advertorial is sponsored by Boston Scientific
The arrival of pulsed-field ablation (PFA) has been heralded by many experts in the field of arrhythmia management...
MANIFEST-17k registry shows promising safety performance for PFA
Pulsed field ablation (PFA) is safe for treating patients with common types of atrial fibrillation (AF), findings of the largest real-world registry of the...
Boston Scientific launches NAVIGATE-PF study
Boston Scientific has initiated the NAVIGATE-PF study of the Faraview software module when it is used to visualise and track the Farawave Nav pulsed...
Biosense Webster submits premarket approval application to US FDA for Varipulse...
Biosense Webster has submitted a premarket approval application (PMA) to the US Food & Drug Administration (FDA) for its Varipulse platform. The submission was...
“Second-generation” PFA catheter developer Field Medical closes seed round
Field Medical has closed its oversubscribed seed round with investments totalling US$14million.
The convertible note funding was led by private investors who were joined by...
ADVERTORIAL: Pulsed field ablation: A new frontier in the treatment of...
This article was sponsored by Biosense Webster
According to data published by Patrick M McCarthy (Feinberg School of Medicine, Chicago, USA) and colleagues in the...
HRS 2023: Late-breaking clinical trial results support PFA as treatment option...
New data from three late-breaking clinical trials has demonstrated the safety and efficacy of pulsed field ablation (PFA) as a viable, non-thermal treatment option...
First patients treated in Kardium PULSAR IDE study of Globe pulsed...
Kardium, a private medical device company that has developed the Globe pulsed field (PF) system for the treatment of atrial fibrillation (AF) using pulsed...
AF Symposium hears late-breaking data from RFA and PFA trials
Biosense Webster has announced an update and late-breaking data from trials across radiofrequency ablation (RFA) and pulsed field ablation (PFA) at the 2023 AF...
Field Medical and CardioNXT to collaborate on 3D integrated PFA therapy
Field Medical and CardioNXT have announced a strategic collaboration to provide the first-of-its-kind focal pulsed field ablation (PFA) therapy integrated with 3D mapping &...
Study reveals low reconnection rate with large antral lesion at PW...
A first-of-its-kind analysis on electrophysiological findings in patients with recurrent atrial tachyarrhythmia (ATa) following pulmonary vein isolation (PVI) using the novel pentaspline pulsed-field ablation...